BEVACIZUMAB INTRAVÍTREO SEGUIDO DE LÁSER FOCAL EN EL EDEMA MACULAR DIABÉTICO DIFUSO DE PROGRESIÓN RECIENTE. CASO CLÍNICO INTRAVITREAL BEVACIZUMAB FOLLOWED BY FOCAL LASER FOR DIFFUSE DIABETIC MACULAR EDEMA OF RECENT PROGRESSION. A CLINICAL CASE

Case report: We report the case of a 48-year-old man with diffuse diabetic macular edema of recent progression treated with two consecutive intravitreal injections of bevacizumab followed by focal laser therapy, with good anatomic and functional response. Discussion: Diffuse diabetic macular edema is difficult to manage and frequently requires multiple therapies. We propose the use of bevacizumab as a strategy to reduce diffuse macular edema, facilitating the application of laser therapy (Arch Soc Esp Oftalmol 2009; 84: 209-212).